B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Cassava Sciences (NASDAQ:SAVA) on Wednesday, setting a price target of $145, which is approximately 23.06% above the present share price of $117.83.
Mamtani expects Cassava Sciences to post earnings per share (EPS) of -$0.13 for the third quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Cassava Sciences, with an average price target of $154.8.
The analysts price targets range from a high of $215 to a low of $100.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$5.14 million. The company's market cap is $4.71 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 17.0% and a 45.77% success rate.
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.